ReviewDiagnostics (Basel, Switzerland)2026
Decoding Cervical Neuroendocrine Carcinoma: A Practical Review of Diagnostic Pitfalls, Differential Diagnosis and Molecular Insights.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent progress and therapeutic strategies in the treatment of cervical neuroendocrine neoplasms (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical neuroendocrine carcinoma (NECC) is a rare but highly aggressive cervical malignancy, accounting for approximately 1% of invasive cervical cancers. Diagnosis is challenging because NECC overlaps morphologically with other poorly differentiated cervical and metastatic tumors, may show crush artifact in small biopsies, and can display variable expression of conventional neuroendocrine markers. This narrative review provides a practical synthesis of the histopathological, immunohistochemical, molecular, and clinical features of NECC, with emphasis on diagnostic pitfalls and differential diagnosis. Recent English-language literature on cervical neuroendocrine carcinoma was reviewed and qualitatively integrated, focusing on morphology, immunohistochemistry, HPV association, molecular alterations, prognosis, and management-relevant diagnostic issues. Accurate diagnosis requires integration of morphology, epithelial differentiation, neuroendocrine marker expression, HPV-related context, and clinic-radiological correlation. Useful markers include broad-spectrum cytokeratins, synaptophysin, chromogranin A, CD56, INSM1, p16, and Ki-67, with additional markers selected according to the differential diagnosis. Diffuse block-type p16 expression and high-risk HPV detection support a cervical HPV-associated origin but are not specific for neuroendocrine differentiation. Molecular studies show frequent association with HPV18 and recurrent alterations involving PI3K/AKT, RAS/MAPK, and TP53-related pathways, although these findings remain insufficiently validated for routine prognostic or therapeutic stratification. NECC requires early recognition and a multimodal diagnostic approach because of its aggressive behavior and poor prognosis. A practical, stepwise integration of morphology, immunohistochemistry, molecular findings, and clinical-radiological data may improve diagnostic consistency and support multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.